Discover how zuranolone (SAGE-217), a first-in-class oral neuroactive steroid, offers rapid relief for major depressive disorder and postpartum depression through short 14-day treatment cycles and a novel GABAA receptor mechanism, reshaping options for treatment-resistant depression.
Learn what zuranolone is, how this first-in-class oral neuroactive steroid works on GABA-A receptors, and why it’s generating buzz as a rapid-acting treatment option for major depressive disorder (MDD) and postpartum depression (PPD).
Learn what zuranolone is, how it works as a fast-acting GABAA-modulating antidepressant, and why it’s a breakthrough for major depressive disorder and postpartum depression, with key clinical trial data on onset, durability, and dosing.